Erkan I, Ciliv G, Remzi D
J Surg Oncol. 1982 Sep;21(1):65-9. doi: 10.1002/jso.2930210117.
Thirty-six patients with prostatic carcinoma and benign prostatic hyperplasia (BPH) were studied. Transurethral resection (TUR) was performed in all, and serum and tissue ribonuclease (RNase) levels were determined with the spectrophotometric method using yeast RNA as the substrate. In patients with untreated prostatic carcinoma, statistically significant increased RNase levels were found in serum and tissue. Treatment with diethylstilbestrol diphosphate (DESDP) led to a decrease in RNase levels. In the same patients RNase serum levels after DESDP treatments also showed a parallel decrease with serum prostatic acid phosphatase (sPAP) levels. We have concluded that the serum RNase measurement may be useful for TNM classification and immunostaging.
对36例前列腺癌和良性前列腺增生(BPH)患者进行了研究。所有患者均接受了经尿道切除术(TUR),并以酵母RNA为底物,采用分光光度法测定血清和组织核糖核酸酶(RNase)水平。在未经治疗的前列腺癌患者中,血清和组织中的RNase水平在统计学上显著升高。使用己烯雌酚二磷酸酯(DESDP)治疗导致RNase水平下降。在同一组患者中,DESDP治疗后的RNase血清水平也与血清前列腺酸性磷酸酶(sPAP)水平呈平行下降。我们得出结论,血清RNase检测可能有助于TNM分期和免疫分期。